NEW YORK, March 10, 2023 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of CVRx, Inc. (“CVRx” or the “Company”) CVRX. Those investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, extension 7980.

The investigation concerns whether CVRx, Inc. and certain of its officers and/or directors have engaged in securities fraud or other illegal business practices.

[Click here for information about joining the class action]

On February 21, 2023, CVRx announced that its BeAT-HF post-market phase study for the approved heart failure therapy Barostim failed to meet its primary endpoint with statistical significance. According to top-line data from BeAT-HF, the study, which included 323 patients with heart failure and reduced ejection fraction, did not meet the primary endpoint of a measure combining cardiovascular mortality and heart failure-related morbidity.

As a result of this news, CVRx’s stock price fell $10.12 per share, or 58.84%, to close at $7.08 per share on February 21, 2023.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris and Tel Aviv, is recognized as one of the leading law firms specializing in corporate, securities and antitrust litigation. Founded by the late Abraham L. Pomerantz, best known as Dean of the Class Bar Association, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues the tradition he founded and fights for the rights of victims of securities fraud, fiduciary breaches and corporate wrongdoing. The firm has recovered numerous multi-million dollar claims on behalf of group members. See www.pomlaw.com.

CONTACT:

Robert S Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980